Proteintech Appoints Patrick Yount as CFO and Promotes Jeb Gaybrick to Lead Corporate Strategy and Investor Relations
Proteintech Group, Inc., a global life sciences company, has announced two leadership changes aimed at supporting its continued growth and preparing the organization for its next phase of development. The company has appointed Patrick Yount as Chief Financial Officer (CFO), effective October 26, 2026, and promoted Jeb Gaybrick to Vice President of Corporate Strategy and Investor Relations.
The appointments strengthen Proteintech’s financial leadership and corporate strategy capabilities as the company continues to expand its business and reinforce its financial infrastructure. With Yount overseeing financial strategy and operations and Gaybrick leading corporate strategy and investor relations, Proteintech is positioning its leadership team to support long-term growth, strategic capital allocation, and organizational development.
The leadership changes bring together extensive financial management experience in the life sciences and healthcare sectors and a background in public-market investing focused on life science tools. Both executives are expected to contribute to the company’s strategic priorities as it advances its next stage of business development.
Proteintech’s announcement reflects the importance of experienced financial and corporate leadership for life sciences companies operating in a competitive research tools market. As businesses in the sector pursue growth opportunities, financial planning, capital allocation, investor engagement, and operational efficiency can play important roles in supporting sustainable development.
Patrick Yount Appointed Chief Financial Officer
Yount will assume the role of Chief Financial Officer on October 26, 2026. In this position, he will serve as a strategic and operational leader, overseeing Proteintech’s financial strategy and finance functions while helping the company sustain its growth trajectory.
His responsibilities will include guiding the company’s financial operations and supporting the development of infrastructure needed to manage its expanding business. The role is also expected to involve aligning financial planning with corporate priorities and ensuring that the company’s financial capabilities can support its future requirements.
For a global life sciences company, the CFO position encompasses more than traditional accounting and financial reporting. Financial leadership can influence investment decisions, resource allocation, operational planning, and the evaluation of strategic opportunities. Yount’s appointment is intended to strengthen these capabilities as Proteintech prepares for its next phase of evolution.
According to the company, Yount brings more than 25 years of executive financial leadership experience across the life sciences and healthcare sectors. His background includes scaling organizations, managing transformative transactions, supporting strategic initiatives, and raising capital in both public and private markets.
These areas of expertise are relevant to companies seeking to expand their operations while maintaining the financial discipline required to support long-term business objectives. Experience with capital raising and strategic transactions can also help organizations assess potential opportunities, manage financial resources, and establish appropriate structures for growth.
Yount’s experience across public and private markets provides a foundation for overseeing financial strategy in an environment where businesses may need to balance operational investment with broader corporate priorities. His background in organizational scaling is particularly relevant as Proteintech seeks to strengthen its financial infrastructure alongside its continued development.
Experience at Active Motif and General Electric
Before joining Proteintech, Yount served as Chief Financial Officer of Active Motif, a manufacturer of epigenetic kits, reagents, and antibodies used by research organizations worldwide.
Active Motif operates in the life sciences research tools market, supplying products that support investigations into epigenetics and related biological processes. Its product portfolio serves researchers who require specialized laboratory tools and reagents for scientific studies.
Yount’s experience as CFO at Active Motif provided him with direct exposure to the financial and operational requirements of a company serving the global research community. This background is relevant to Proteintech, which also operates in the life sciences sector and serves researchers through its scientific product offerings.
His previous responsibilities at Active Motif are complemented by experience in strategic transactions and capital raising. Together, these capabilities provide a broad financial leadership background spanning corporate operations, financial planning, and strategic business development.
Yount began his finance and accounting career at General Electric Company, where he participated in GE’s Financial Management Program. The program provided an early foundation in financial management and corporate operations.
His career progression from an initial finance and accounting role to executive financial leadership positions reflects more than two decades of experience in business finance. Through his work in the life sciences and healthcare industries, he has developed experience relevant to companies managing complex operations and pursuing growth opportunities.
At Proteintech, this experience is expected to support the company’s financial decision-making, strengthen its internal financial infrastructure, and help ensure that financial planning remains aligned with its strategic direction.
Jeb Gaybrick Promoted to Vice President of Corporate Strategy and Investor Relations
Alongside Yount’s appointment, Proteintech has promoted Jeb Gaybrick to Vice President of Corporate Strategy and Investor Relations.
Gaybrick joined Proteintech in 2025 as Director of Investor Relations. In his expanded role, he will lead both corporate strategy and investor relations, with a particular focus on strategic capital allocation.
The promotion broadens Gaybrick’s responsibilities beyond investor communications to include a more direct role in shaping the company’s corporate strategy. By bringing these functions together under one leader, Proteintech aims to align its strategic priorities with investor engagement and capital allocation decisions.
Corporate strategy involves evaluating business opportunities, establishing priorities, and determining how resources should be deployed to support organizational objectives. Strategic capital allocation, meanwhile, focuses on directing financial resources toward activities that can contribute to the company’s development and long-term performance.
Combining these responsibilities with investor relations may help create closer coordination between the company’s strategic direction and its communication with investors and other financial stakeholders.
Gaybrick’s background in public markets and life science tools investing is expected to inform this work. His experience provides familiarity with how investors assess companies in the sector, evaluate business fundamentals, and consider the long-term potential of research tools businesses.
Proteintech’s decision to expand Gaybrick’s responsibilities also reflects the value of continuity in corporate strategy and investor relations. Having joined the company in 2025, he already has experience within the organization and is familiar with its business and investor engagement activities.
In his new position, he will be responsible for bringing this knowledge together with his investment background to support corporate planning and capital allocation.
Public-Market Investment Experience
Before joining Proteintech, Gaybrick spent 18 years working in public markets, focusing on the life science tools industry.
This experience gave him a substantial background in evaluating companies operating in a sector that supplies products, technologies, and research materials to scientific organizations. The life science tools industry serves a broad range of research applications, including laboratory investigations, biotechnology development, and pharmaceutical research.
Companies in this market must navigate scientific demand, competitive pressures, investment requirements, and evolving research priorities. An understanding of public-market expectations can help corporate leaders assess strategic options and communicate business priorities to investors.
Gaybrick also led 12 West Capital’s investment in Proteintech in October 2020. His involvement in that investment gives him a historical connection to the company that predates his appointment as Director of Investor Relations.
His transition from public-market investing to an internal leadership role at Proteintech provides the company with an executive who has experience assessing the business from an investor’s perspective and now holds responsibilities for corporate strategy and investor relations.
This combination may be useful as Proteintech evaluates strategic opportunities, considers the deployment of capital, and communicates its priorities to relevant stakeholders.
While the company has not disclosed specific new strategic initiatives or capital allocation plans alongside the promotion, the expanded role establishes a clear leadership structure for these responsibilities.
Leadership Changes Support Proteintech’s Next Phase of Growth
The appointments of Yount and Gaybrick represent a coordinated strengthening of Proteintech’s financial and strategic leadership.
Yount will focus on the financial management and operational infrastructure needed to support continued growth, while Gaybrick will lead corporate strategy and investor relations, emphasizing the allocation of capital in line with the company’s priorities.
Together, the roles cover complementary aspects of corporate development. Financial leadership supports effective management of resources and the infrastructure required to operate at scale. Corporate strategy helps determine where those resources should be directed, while investor relations communicates the company’s priorities and developments to financial stakeholders.
For a life sciences business, these functions can become increasingly important as the organization develops its operations and evaluates opportunities for future expansion.
Yount’s background in finance, capital raising, and strategic transactions brings experience in managing the financial dimensions of business development. Gaybrick’s experience in public markets and life science tools investing adds a perspective on investment decisions and the expectations of financial stakeholders.
Their appointments are intended to provide Proteintech with the leadership capabilities needed to support its next phase of growth and long-term objectives.
The changes also reflect an emphasis on aligning operational capabilities with strategic planning. As companies expand, financial systems and processes may need to evolve alongside business requirements. Experienced financial leadership can help ensure that the organization’s infrastructure is positioned to support its operational needs, while corporate strategy can help establish priorities for future investment.
Proteintech has not announced additional organizational changes or provided specific financial targets in connection with these appointments. However, the company has emphasized the importance of strengthening its leadership team as it prepares for the next stage of its development.
CEO Highlights Importance of Experienced Leadership
Dr. Jason Li, Chief Executive Officer of Proteintech, welcomed both executives to the company’s leadership team and emphasized their experience and anticipated contributions.
“We are excited to welcome Patrick and Jeb to our leadership team at a pivotal time for the Company. As we continue to grow and prepare for the next phase of our evolution, we recognize the importance of having experienced financial and corporate leaders. Both bring the expertise and leadership we need to support our growth and position the Company for long-term success,” Li said.
The CEO’s comments underscore the company’s focus on strengthening its financial and corporate leadership as it continues to develop its business.
The appointments bring together different but complementary areas of expertise. Yount’s experience in executive finance, capital raising, and organizational scaling is expected to support financial management and operational development. Gaybrick’s background in public markets, life science tools investing, and investor relations is expected to contribute to corporate planning and strategic capital allocation.
Proteintech’s leadership changes also establish a structure in which financial oversight and corporate strategy can work in coordination as the company evaluates its future priorities.
With Yount’s appointment effective October 26, 2026, and Gaybrick’s promotion to Vice President of Corporate Strategy and Investor Relations, Proteintech is strengthening the leadership functions responsible for financial management, strategic planning, and investor engagement.
The company expects the executives’ combined experience to support continued growth and help position the organization for long-term success.
Yount brings more than 25 years of financial leadership experience, including his most recent role as CFO of Active Motif and his early career at General Electric. Gaybrick contributes 18 years of public-market experience focused on life science tools, alongside his work at Proteintech and his role in leading 12 West Capital’s October 2020 investment in the company.
As Proteintech moves into its next phase of development, these appointments are intended to reinforce its financial infrastructure, support informed capital allocation, and align corporate strategy with its broader growth objectives. The company has positioned the leadership changes as an important step in ensuring it has the financial and strategic expertise required to pursue its long-term ambitions in the global life sciences market.
About Proteintech
Founded in 2001, Proteintech Group, Inc. identifies, manufactures, and commercializes antibodies, immunological reagents, and workflow solutions, serving customers across academic institutions, research organizations, and diagnostics and biopharmaceutical companies. The company’s products are used by customers globally across rapidly growing research fields, including oncology, immunology, neurology, cardiology, and metabolic diseases. The Company’s portfolio of more than 77,300 self-manufactured antibodies covers approximately two-thirds of the human proteome, with more than 500,000 citations in academic life science publications worldwide.